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Introduction
Precise regulation of post-translational protein acetylation/
deacetylation is vital to normal physiological homeostasis, and 
includes essential biological processes such as transcription 
factor-to-DNA binding, chromatin structure (thus influencing 
gene expression), “chaperone”-mediated protein stabilization 
and intracellular transport.1,2 Consequently, alterations in the 
balance of acetylation and deacetylation contributes to several 
previously, we demonstrated potent antineoplastic activity of a distinctive histone deacetylase inhibitor (hDaCI), ar42, 
against chemoresistant Cp70 ovarian cancer cells in vitro and in vivo. here, in follow-up to that work, we explored ar42 
global mechanisms-of-action by examining drug-associated, genome-wide microrNa and mrNa expression profiles, 
which differed from those of the well-studied hDaCI vorinostat. expression of microrNa genes in negative correlation 
with their “target” coding gene (mrNa) transcripts, and transcription factor genes with expression positively correlated 
with coding genes having their cognate binding sites were identified and subjected to gene ontology analyses. Those 
evaluations showed ar42 gene expression patterns to negatively correlate with Wnt signaling (> 18-fold induction of 
SFRP1), the epithelial-to-mesenchymal transition (40% decreased ATF1) and cell cycle progression (33-fold increased 
14-3-3σ). By contrast, ar42 transcriptome alterations correlated positively with extrinsic (“death receptor”) apoptosis 
(> 2.3-fold upregulated DAPK) and favorable ovarian cancer histopathology and prognosis. Inhibition of Wnt signaling 
was experimentally validated by: (1) >2.6-fold reduced Wnt reporter activity, and (2) 36% reduction in nuclear, activated 
β-catenin. ar42 induction of multiple (type I or type II autophagic) cell death cascades was further supported by 57% 
decreased reliance upon reactive oxygen, increased mitochondrial membrane disruption and caspase independence, 
as compared with vorinostat. Taken together, we demonstrate distinct antineoplastic pathway alterations, in aggressive 
ovarian cancer cells, following treatment with a promising hDaCI, ar42. These combined computational and experimental 
approaches may also represent a straightforward means for mechanistic studies of other promising antineoplastics, and/
or the identification of agents that may complement epigenetic therapies.
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pathologies, including cancer, metabolic disorders, neurodegen-
erative conditions and inflammation.1,2
In the late 1990s, mechanistic studies of a number of leuke-
mia cell-differentiating hydroxamic acids revealed these agents 
to enhance histone acetylation, via the inhibition of histone 
deacetylase enzymes.3 Subsequent preclinical and clinical studies 
led to FDA approval of two such “histone deacetylase inhibitors” 
(HDACIs), suberoylanilide hydroxamic acid (SAHA, vorinostat) 
and the cyclic peptide romidepsin (depsipeptide), for cutaneous 
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Results
HDAC inhibitor effects on microRNA and mRNA expression. 
Previously, we demonstrated AR42 to differentially resensitize 
drug-resistant ovarian cancer cells and xenograft tumors to cispl-
atin, in parallel with the well-known HDACI vorinostat.6 Based 
on that work, and other studies showing HDACI effects on 
microRNA (miRNA) expression,22-26 we further compared AR42 
and vorinostat for differential effects on global miRNA and pro-
tein-coding gene (mRNA) expression levels. In accord with their 
similar structure/functional groups (hydroxamic acids, which act 
to chelate the essential HDAC cofactor Zn2+),5 the two HDACIs 
exerted comparable expression effects on a large number of genes 
(Fig. 1A). However, hierarchical clustering analysis also revealed 
distinct gene expression patterns (“clusters”) between duplicate 
arrays of untreated, AR42- and vorinostat-treated CP70 cells 
(Fig. 1A). Likewise, while AR42 and vorinostat similarly altered 
the expression of several miRNA genes, we also observed the two 
HDACI miRNA profiles to distinctly cluster, as compared with 
the untreated (DMSO vehicle) control (Fig. 1B and C). These 
discrete miRNA and gene expression clusters validated sample 
reproducibility (thus qualifying the data for additional analyses), 
thus justifying further examination of the genome-wide effects of 
AR42 on signal transduction pathways.28,29
Functional analyses of AR42 alterations in protein-coding 
and microRNA gene expression. To examine the global bases 
for the antineoplastic effects of AR42, we first identified tran-
scription factor (TF) binding sites (TFBSs) localized within 
4,000 bp of the transcription start sites of AR42-differentially 
expressed genes (Fig. 1A and B), using the webtool ECR (evo-
lutionary conserved region) Browser.30 We then examined the 
expression of TFs matching those TFBSs, followed by assay of 
TF expression changes with those of their TFBS-possessing “tar-
get” genes.30,31 The matched TF/target genes were then subjected 
to Gene Ontology (GO) analysis, using the web tool BiNGO,32 
revealing AR42-associated gene expression profiles to negatively 
correlate with the GO biological processes “epithelial-to-mesen-
chymal transition” (EMT, GO: 0001837) and “canonical Wnt 
receptor signaling” (GO: 0060070) (Table 1). Consistent with 
AR42 negative regulation of those tumor progression cascades, 
we also noted upregulation of genes repressive of the EMT (e.g., 
ONECUT2, WT1) and Wnt (e.g., SFRP1 ICAT, TAK1) path-
ways (Tables 2 and 3, respectively). By contrast, the expression 
of AR42-altered TF/target gene transcription positively corre-
lated with the GO terms “negative regulation of cell cycle pro-
cesses” (GO: 0010948) (Table 4) and “induction of apoptosis 
by extracellular signals” (i.e., extrinsic apoptosis, GO: 0008624) 
(Table 5). With regard to the latter two pathways, and in contrast 
with the Wnt and EMT cascades, AR42-upregulated agonists 
(14-3-3σ, p21, DAPK and RIP), and downregulated antagonists 
(TopoII, BCL2) of cell cycle arrest and death receptor signaling 
(Tables 4 and 5). Overall, these four AR42-associated GO path-
ways concur with our previously observed AR42 antineoplastic 
effects on ovarian cancer cells, including G
2
/M cell cycle arrest 
(via repression of genes that stimulate that pathway), induction 
of epithelial morphology and extensive apoptosis (following 
T-cell lymphoma.4 Likewise, recent clinical trials of hematologic 
cancers demonstrated efficacy of other hydroxamate HDACIs, 
including belinostat, panobinostat and SB939, while promis-
ing non-hydroxamate HDACIs include entinostat (formerly 
MS-275), apicidin, and an isoform-selective HDACI, moceti-
nostat (previously MGCD0103) (for more extensive HDACI 
review, see refs. 3 and 4). Preclinical studies by our group and 
others have similarly shown potential therapeutic efficacy of a 
“rationally designed” HDACI, AR42 (formerly OSU-HDAC42, 
Arno Therapeutics),5 against multiple myeloma, adult T-cell 
lymphomas and solid tumors of the ovary, liver and prostate, 
both singly or combined with other agents.6-12
Various molecular mechanisms/processes have now been 
advanced to explain HDACI cancer cell-specific cytotoxicity 
(and non-toxicity toward normal cells), including upregulation 
of pro-apoptotic genes, downregulation of anti-apoptotic genes, 
abrogation of cell cycle checkpoints and increased production 
of reactive oxygen species (concurrent with diminished anti-
oxidative response).2,4 With some exceptions, however, many of 
those previously identified anticancer mechanisms were based 
on limited numbers of HDACI-altered genes, absent rigorous 
assessments of HDACI cumulative effects on signal pathways/
networks.2,4 In ovarian cancer specifically, clinical trials of single-
agent HDACIs have shown marginal activity against high-grade 
serous (HGS) disease, but some efficacy against borderline can-
cer.13,14 Several preclinical studies of HGS ovarian cancer, how-
ever, have demonstrated potent antitumor activity of HDACIs 
when combined with conventional therapies, likely via resensi-
tization of drug-resistant subclones (reviewed in refs. 14–16). 
However, the precise mechanism(s) of HDACI-mediated chemo-
sensitization, with regard to specific signal pathways/networks, 
remains somewhat speculative.4,15
In concert with aberrant protein acetylation, dysregulated 
expression of microRNAs (miRNAs) is also strongly linked 
to the progression of numerous solid tumors, including ovar-
ian cancer.14,17-21 Even so, relatively few reports have described 
HDACI effects on these non-coding, post-transcriptional gene 
product regulators. In chronic lymphocytic leukemia cells, 
the HDACI LAQ824 was shown to upregulate three silenced 
tumor suppressive miRNAs,22 while HDACI treatment resulted 
in upregulation of 22, and downregulation of 10 miRNAs in 
breast cancer cells.23 Similarly, numerous miRNAs were found 
dysregulated by vorinostat in colon24 and lung25 cancer cells (in 
concert with p53 gain-of-function), while LAQ824 altered the 
expression of over 60 miRNAs in breast cancer cells.26 Another 
miRNA study, however, reported no HDACI effects on miRNA 
expression, using a panel of 91 cancer cell lines.27 Consequently, 
in this follow-up to our previous study of AR42 chemosensi-
tizing activity in vitro and in vivo,6 we assessed the genome-
wide effects of AR42 on both miRNA and protein-coding 
(mRNA) gene expression in drug-resistant ovarian cancer cells. 
Bioinformatic analyses of this data, combined with experimen-
tal validation, revealed AR42 to exhibit discrete (but likely 
cooperative) pleiotropic effects on multiple signal pathways 
that may jointly oppose progression of this lethal gynecological 
malignancy.
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cells,34 again supporting an AR42 inversely correlated expres-
sion profile (Fig. 2B). Likewise, for Wnt signaling, we compared 
AR42 changes in gene expression to a publically available Wnt-
upregulated gene signature (KEGG pathway hsa04310).35 Similar 
to the inverse EMT profile, AR42 downregulated the majority of 
those (Wnt-upregulated) signature genes (Fig. 2C), thus further 
supporting AR42 inhibition of Wnt signaling.
Similarly, we compared AR42 expression changes to other 
gene signatures of cell cycle arrest and death receptor-mediated 
apoptosis. Those evaluations revealed that in contrast to the EMT 
and Wnt pathways, AR42 transcriptional changes positively cor-
related with cell cycle arrest (KEGG pathway map04110) and 
death receptor apoptosis (MSigDB identifier M16635) gene 
expression signatures35 (Fig. 3A and B, respectively). Within 
the cell cycle arrest signature, we noted upregulation of the 
AR42 treatment in combination with the DNA-crosslinking 
agent cisplatin).6
Concordance of AR42 microRNA and mRNA expression 
profiles to pathway “gene expression” signatures. To further 
extend our functional analysis and provide greater mechanistic 
detail of AR42 antineoplastic activity, we examined drug-asso-
ciated gene profiles for alignment to various published “gene 
expression signatures.” To first affirm that AR42 effects were 
indeed due to deacetylase inhibition, we showed AR42 gene alter-
ations to positively correlate with an “HDAC inhibitor common 
gene set” expression signature33 (Fig. 2A), including upregulation 
of CDNK1A (p21CIP1), a “benchmark” gene induced by all inhibi-
tors of class I and class II HDACs.2,4
We also examined the AR42 transcriptome for expression 
of signature genes downregulated by EMT in breast cancer 
Figure 1. Unsupervised cluster analysis of (a) coding-gene expression (Nimblegen 385K Gene expression); (B) downregulation mature microrNas; 
and (C) upregulation of mature microrNas. Microarray data (124-feature custom array)71 was subjected to quantile normalization72 and unsupervised 
clustering performed using eXpaNDer.29
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results concur with our prior observation of AR42-associated cell 
cycle arrest and epithelial differentiation, and previous studies 
demonstrating AR42 repression of oncogenic cascades, concur-
rent with derepression of tumor suppressive regulators, in various 
cancer types.5-11
We also examined AR42 for disease-specific activity against 
ovarian cancer, by comparing AR42 expression patterns to two 
ovarian cancer clinically informative transcription signatures. 
Those analyses demonstrated AR42 expression changes to posi-
tively correlate with gene expression signatures for favorable 
prognosis38 and low-grade serous (as compared with high-grade 
serous, HGS) disease39 (Fig. 4). To further support specific anti-
tumor activity against HGS malignancy, we also observed AR42 
downregulation of various ovarian cancer oncogenic miRNAs, 
including miR-21 and miR-30 (Fig. 1B),18,21 and upregulation 
of previously reported ovarian tumor-suppressive miRNAs, 
including those of the let-7 family and miRs 99, 100 and 125 
17,19,21 (Fig. 1C). Moreover, two other AR-42-upregulated miR-
NAs, miR-15 and miR-34 (a p53 target gene), were previously 
reported as epigenetically downregulated in ovarian cancer.17,19 
Taken together, these gene set enrichment and ontology analyses 
support AR42 anti-ovarian cancer activity by circumvention of 
two aggressive tumor progression cascades, EMT and Wnt, coin-
cident with upregulation of two growth-limiting cascades, cell 
cycle arrest and death receptor signaling.
Experimental assessment of AR42 effects on Wnt pathway 
signal transduction. Based on our GO analyses (Table 1), we 
validated expression levels of selected genes from the various 
abovementioned pathways by quantitative, reverse transcription 
PCR (qRT-PCR), affirming upregulation of the Wnt antago-
nists SFRP1 and TAK1, the cell cycle inhibitor 14-3-3σ, and 
downregulation an EMT-activating TF gene, ATF1 (Fig. 5A). 
To further assess the effects of AR42 on Wnt pathway signal-
ing, we transfected CP70 cells with the Wnt luciferase reporter 
TOPFlash and its negative control, FOPFlash,40 followed by 48-h 
treatment with vehicle or 1.0 μM AR42. As shown in Figure 5B, 
AR42 treatment resulted in > 2.6-fold decreased Wnt activ-
ity (luciferase activity). We also examined AR42 effects on the 
Wnt signal mediator β-catenin, which is dephosphorylated upon 
activation, followed by translocation to the nucleus.40-42 Using 
an antibody specific for dephosphorylated (and thus activated) 
β-catenin, we determined that AR42 caused a 57% decrease in 
nucleus-localized protein and a 23% decrease in cytoplasmic 
cyclin-dependent kinase inhibitors CDKN1A (p21CIP1), CDKN1B 
(p15INK4B) and CDKN2D (p19INK4D), in addition to the p53 target 
gene and coactivator 14-3-3σ (Table 4). Interestingly, we also 
noted a slight (0.7-fold) downregulation of p53 (Fig. 3A), which 
is overexpressed and dysfunctional in CP70 cells (likely con-
tributing to chemotherapy resistance).36,37 These gene signature 
Table 1. Gene ontology (GO) terms identified from gene expression changes following 48-h ar42 treatment
Gene ontology (GO) term GO accession/ontology Biological function
INDUCTION_OF_apOpTOsIs_ 
INDUCTION_BY_eXTraCeLLULar_sIGNaLs
GO: 0008624 
Biological process
programmed cell death initiated by extracellular ligand death 
receptor binding/signal transduction
NeGaTIVe_reGULaTION_OF_CeLL_CYCLe_prOCess
GO: 0010948 
Biological process
Inhibition of DNa synthesis, degradation of cyclin/CDK  
complexes, activation of checkpoints
epITheLIaL_TO_MeseNChYMaL_TraNsITION
GO: 0001837 
Biological process
Loss of cell-cell contact, migration, invasion
CaNONICaL_WNT_reCepTOr_sIGNaLING_paThWaY
GO: 0060070 
Biological process
embryonic development pathway, mitogenic signaling for cell 
proliferation
Table 2. Microarray ar42-induced expression changes in gene  
members of the GO term epITheLIaL_TO_MeseNChYMaL_TraNsITION
Genes (gene 
symbol)
Fold change 
(AR42/Control)
Hypothesized role in EMT
PAX2 33.0
inhibitory (sequesters cdc2/cyclin B1 
complex in cytoplasm)
GATA6 5.2 cell differentiation/specialization
WT1 1.3 negative regulator of eMT
SOX2 0.6
facilitator of eMT, induced pluripotency 
gene
ATF1 0.6 eMT-associated transcription factor
ONECUT2 2.8
tissue lineage  
commitment/differentiation
Table 3. ar42-induced changes in members of the GO term  
CaNONICaL_WNT_reCepTOr_sIGNaLING_paThWaY
Genes  
(gene symbol)
Fold-change 
(AR42/control)
Wnt signaling function
SFRP (SFRP1) 18.9 Wnt signal inhibitor
WIF (WIF1) 1.7 Wnt target gene repressor
PIN1 0.7 Wnt signal mediator
ICAT (CTNNBIP1) 2.2 Wnt signal inhibitor
APC 1.3 Wnt signal inhibitor
Naked (NKD1) 2.3 Wnt target gene repressor
CTBP (CTBP1) 0.9 Wnt target gene repressor
NLK 1.5 Wnt target gene repressor
DKK (DKK1) 1.2 Wnt signal inhibitor
Groucho (TLE1) 2.9 Wnt target gene repressor
Groucho (TLE2) 0.66 Wnt target gene repressor
Groucho (TLE3) 1.8 Wnt target gene repressor
TAK1 (MAP3K7) 2.8 Wnt signal inhibitor
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mouse xenografts by a distinctive histone deacetylase inhibitor 
(HDACI), AR42.6 While several reports have associated HDACI 
anticancer activity with limited numbers of altered genes,2,47,48 
here we endeavored to assess global mechanisms (i.e., pathways/
networks) of AR42 cancer cell-specific cytotoxicity, using a 
“systems biology” approach.28,29,35 Moreover, with regard to the 
now well-established role of misexpressed (and frequently epi-
genetically altered) microRNAs (miRNAs) in ovarian tumori-
genesis,14,17-19,21 we also considered dysregulation of these short, 
non-protein-coding, translation-regulatory oligonucleotides. 
protein (Fig. 5C and D). Taken together, these computational 
and experimental results provide additional support for Wnt sig-
nal blockade as a mechanism of AR42 disruption of ovarian can-
cer malignant phenotypes.
Experimental evaluation of AR42 induction of extrinsic 
(death receptor) apoptosis. In accord with our AR42 functional 
analyses described above, several other HDACIs have also been 
demonstrated to induce cell death via “death receptor” (extrinsic) 
apoptosis,2,15 a process that can occur in a mitochondria-indepen-
dent manner (although “crosstalk” with mitochondrial apoptosis 
pathways may also take place).43 Previously, we demonstrated 
that combined AR42/cisplatin treatment resulted in caspase 
activation in CP70 cells and xenografts.6 While caspase induc-
tion associates with both the intrinsic (via intracellular signal-
ing) and extrinsic apoptosis pathways,43,44 caspase-independent 
cell death has also been associated with mitochondrial disrup-
tion.44,45 Consequently, based on our gene ontology (Table 5) 
and gene expression signature analyses (Fig. 3B and Table 5), we 
assessed CP70 cell AR42 treatment in the presence or absence of 
the pan-caspase inhibitor z-VAD-fmk.45 As shown in Figure 5A, 
caspase inhibition had little effect on AR42 dose-dependent 
growth inhibition. We then further investigated possible loss 
of mitochondrial membrane integrity and production of reac-
tive oxygen species (ROS), two events that can also occur dur-
ing extrinsic apoptosis and type II (autophagic) cell death43-45 in 
48-h AR42- and/or vorinostat-treated cells. With specific regard 
to ROS dependence, 48-h, HDACI-treated CP70 cells concur-
rently exposed to 15 mM of the antioxidant N-acetylcysteine 
(NAC) demonstrated a 37-fold increased 50% growth-inhibitory 
(GI
50
) dose for vorinostat (thus showing vorinostat as 37-fold less 
apoptotic in the absence of ROS). In contrast, NAC treatment 
increased the AR42 GI
50
 by only 21-fold (Fig. 6B), suggesting 
AR42-induced cell death as less dependent on ROS production.
Caspase-independent cell death and ROS production may 
also associate with mitochondrial membrane permeation (and 
thus loss of mitochondrial membrane potential, ΔΨ).43 To exam-
ine possible effects on mitochondrial integrity, we used a fluo-
rescent ΔΨ reporter, JC-1,46 following 48-h CP70 cell treatment 
with 1.0 μM AR42 or 1.0 μM vorinostat. At normal ΔΨ, JC-1 
self-aggregates in the inner mitochondrial space, with aggregated 
JC-1 fluorescing red. By contrast, disrupted ΔΨ results in failed 
mitochondrial aggregation of the lipophilic dye, with the result-
ing (cytosolic) JC-1 monomers fluorescing green.46 As shown in 
Figure 6B, following 48-h, 1.0 μM HDACI treatment, green 
fluorescence (i.e., monomeric and cytosolic JC-1) was predomi-
nant in AR42-treated cells (upper part), while red fluorescence 
(mitochondria-aggregated JC-1) was more pronounced in vorino-
stat-treated cells (lower part). These results suggest that at equal 
dose exposures, AR42 elicits greater loss of ΔΨ than vorinostat, 
in possible partial independence from ROS production and cas-
pase activity.43,44
Discussion
In an earlier study, we examined growth suppression and 
drug-sensitization of chemoresistant ovarian cancer cells and 
Table 4. selected ar42-altered genes in the GO term  
NeGaTIVe_reGULaTION_OF_CeLL_CYCLe
Genes  
(gene symbol)
Fold-change 
(AR42/control)
Role in cell cycle progression/
arrest
Chk2 1.3 G1/s arrest (inhibits cdc25)
Wee1 1.5
G2/M arrest (inhibits cdc2/cyclin B1 
complex)
TopoII 0.8
stimulation by DNa helicase activ-
ity involved in DNa replication
14–3-3σ 33.0
Inhibitory (sequesters cdc2/cyclin 
B1 complex in cytoplasm)
CDKN1A (p21WAF1A) 22.4
Inhibitor of cyclin-dependent 
kinase-1
CDKN2B (p15INK4B) 1.7
Inhibitor of cyclin-dependent 
kinase-4
CDKN2C (p18INK4C) 1.8
Inhibitor of cyclin-dependent 
kinase-4
CDKN2D (p19ARF) 2.2
G2/M arrest (releases p53 from 
MDM2)
Table 5. selected ar42-altered genes in the GO term  
apOpTOTIC_prOCess
Genes (gene 
symbol)
Fold change 
(AR42/control)
Death receptor signaling function
ASK1 2.4 signal kinase
APO2/TRAIL 1.7 Death ligand
BAX 1.6
Mitochondrial membrane  
permeabilization
BCL2 0.6 Inhibitor of mitochondrial disruption
BID 2.0
permeabilizes mitochondrial membrane, 
facilitating the release of cytochrome C
DAPK 2.6 signal kinase
DAXX 2.3 adaptor/signal mediator
DR3 1.8 Death ligand receptor
MKK7 0.6 Mitogenic signal kinase
RIP 2.6 apoptosis signal mediator
TRADD 1.4
Death domain adaptor (relays death  
signal from receptor)
TNFR1 1.7 Death ligand receptor
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In addition to chemosensitization, we previously demon-
strated AR42 to differentially enhance protein acetylation and 
alter the expression of specific cell cycle-associated genes, in 
parallel with the HDACI vorinostat.6 In the current work, com-
parisons of AR42- and vorinostat-altered microRNAomes and 
transcriptomes revealed distinct expression clusters (Fig. 1). This 
finding is consistent with earlier demonstrations of specific gene 
expression profiles for distinct HDACIs, possibly related to dif-
ferences of inhibitor “fit” into the HDACI enzyme active site, 
HDAC-isoform preference(s), varying spatiotemporal HDAC 
enzyme location, and/or indirect (secondary, “downstream”) 
transcriptional effects.2 However, while AR42 effects on miRNA 
expression were not previously studied in-depth, our finding of 
its distinctive transcriptome profile, as compared with that of 
vorinostat (Fig. 1A), concurs with previously reported differences 
in gene expression by these two HDACIs.6-9
As vorinostat has now been extensively characterized and 
approved for human use for over five years,2,3 we directed our 
focus on characterizing global anticancer mechanisms of the 
“third generation” HDACI, AR42.5 To further evaluate AR42 
mechanisms, at the biological pathway/network signal level,28,29 
we identified transcription factor (TF) genes whose expression 
correlated positively with that of their “target” genes (i.e., genes 
possessing specific binding sites for those TFs), followed by gene 
ontology (GO) assessment32 (Table 1). Those analyses showed 
that expression of AR42-altered TF target genes (mRNAs) anti-
correlated with the biological processes epithelial-to-mesenchymal 
Although a few studies have examined HDACI antineoplastic 
miRNA alterations,22-27 to our knowledge, the current work rep-
resents the first appraisal of monotherapeutic HDACI effects on 
miRNA expression, (in association with altered signaling path-
ways) in ovarian cancer.
In earlier studies as monotherapies, HDACIs were found 
to induce only small numbers of genes, with greater gene re-
expression requiring cotreatment with another class of epigen-
etic derepressive agents, DNA methyltransferase inhibitors 
(DNMTIs).47,48 Later reports, however, showed single-agent 
HDACIs to dysregulate (both induce and repress) considerably 
more genes.2,4,8,9 Interestingly, one recent report demonstrated 
DNMTIs to only marginally enhance HDACI antineoplastic 
activity in ovarian cancer cells and mouse xenografts.49 The basis 
for recent demonstrations of greater HDACI gene dysregulation 
is somewhat uncertain, but could be related to previously used 
suboptimal or toxic doses, non-ideal durations of treatment, or 
secondary “downstream” gene regulatory events.2 Even more 
impressively (but also controversially), several HDACIs have 
now been reported to reverse other (histone deacetylation-unre-
lated) repressive epigenetic modifications, including methylation 
of deoxycytosine, gain of gene-activating and/or loss of gene-
repressive histone modifications (e.g., lysine methylation).50-52 
Regardless of the extent of HDACI epigenomic reprogramming, 
however, it is widely held that these agents will be most beneficial 
when combined with conventional and/or targeted therapies, as 
demonstrated by our group6 and others.4,15,16,53,54
Figure 2. Comparison of ar42-associated gene expression changes for alignment with expression signatures for (a) genes commonly altered by 14 
separate hDaCIs;33 (B) a set of 100 genes downregulated in cancer cells undergoing the epithelial-to-mesenchymal transition34 and (C) an 84-gene 
signature of upregulated genes in cancer cells possessing active signaling of the oncogenic mitogenic pathway Wnt (KeGG pathway hsa04310).35
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expression of multiple cytokeratins.6 Additionally, while we did 
not examine Akt signaling in the current study, others have dem-
onstrated that Akt signal inhibition (by AR42 and other agents) 
sensitized CP70 and other p53-dysfunctional, drug-resistant, 
ovarian cancer cells.37,56 As AR42 has also been demonstrated to 
downregulate Akt activity,7-9,12 blockade of that oncogenic signal 
pathway might represent another HDACI mechanism of resensi-
tization of chemoresistant ovarian cancer cells (an antineoplastic 
effect we previously observed).6
Similar to EMT, gene set enrichment analysis35 also dem-
onstrated AR42 gene expression profiles to negatively associate 
transition (EMT) (Fig. 2B and Table 2), with upregulation of 
EMT-opposing TFs (GATA6 and WT1), and downregulation 
of EMT-promoting TF genes (SOX2 and ATF1) (Table 2 and 
Fig. 5A). While primary high-grade serous ovarian tumors actu-
ally gain epithelial attributes (i.e., undergo “MET”), late-stage 
disease phenotypes, including metastatic dissemination (“perito-
neal seeding”), chemotherapy resistance (as exhibited by CP70 
cells) and angiogenesis likely associate with restoration of the 
EMT program.14,55 Our current finding (possible EMT reversal) 
is consistent with our previous observation of AR42 induction of 
CP70 epithelial characteristics, based on cell morphology and the 
Figure 3. assessment of ar42-altered expression patterns for signatures of (a) genes upregulated during cell cycle arrest (KeGG pathway map04110),35 
and (B) genes upregulated during “death receptor” (extrinsic) apoptosis (MsigDB identifier M16635).35
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various ovarian cancer-repressed microRNAs, including miR-
99, miR-100, and the miR-125 and let-7 families18-20,58 (Fig. 1C). 
Upregulation of miR-125 as a possible AR42 anti-ovarian cancer 
mechanism was also supported by a demonstration that miR-125 
is repressed by epidermal growth factor signaling, and that miR-
125 re-expression causes reversal of EMT.20 Moreover, consistent 
with HDACI-mediated chromatin relaxation, we also observed 
AR42 to upregulate two miRNAs previously shown as epigeneti-
cally silenced in ovarian cancer, miRs 15a and 34 (Fig. 1C).17,19
Experimental examination of Wnt pathway signaling (by a 
luciferase reporter assay) demonstrated Wnt activity to be 2.6-
fold downregulated by AR42, consistent with other reports of 
HDACI inhibition of the Wnt cascade.42,59,60 While overactive 
Wnt signaling often correlates with activating β-catenin muta-
tions (and/or inactivating mutations of Wnt antagonists), many 
cancers (including ovarian) exhibit elevated Wnt signaling in the 
absence of Wnt pathway genetic alterations.41,42,61 These findings 
with the EMT-dependent oncogenic signal cascade, Wnt (KEGG 
pathway hsa04310, Fig. 2C), while positively correlating with cell 
cycle antagonism (MSigDB_GO: 0007050, Fig. 3A) and extrin-
sic (“death receptor”) apoptosis (MSigDB_M14971, Fig. 3B). 
We also note that in hepatocellular cancer cells, AR42 was found 
to potentiate type II, caspase-independent cell death via autoph-
agy,11 similar to vorinostat.57 In the current work, we likewise saw 
AR42 downregulation of the anti-autophagy gene BCL2, and 
upregulation of two pro-autophagy genes, CHAF1A (p150) and 
BECN1 (Beclin1) (Fig. 1A). However, we also observed downreg-
ulation of pro-autophagy (UVRAG, BNIP3), and upregulation of 
an anti-autophagy gene (AKT1S1) (Fig. 1A), thus confounding 
firm conclusions regarding that type II cell death process.
With specific regard to ovarian cancer, we also found 
AR42-induced gene transcription patterns to correlate with 
gene signatures of favorable ovarian cancer prognosis (Fig. 4A) 
and low-grade disease (Fig. 4B);38,39 AR42 also upregulated 
Figure 4. Ovarian cancer-specific gene signature alterations by ar42 (a) with positive vs. negative ovarian cancer patient prognosis. Upper group 
represents genes whose expression correlates with favorable prognosis; lower group represents genes expressed in unfavorable prognosis (reviewed 
in ref. 38). (B) ar42 alterations of genes correlated with low-grade ovarian adenocarcinoma histopathology upper gene group are upregulated with 
low-grade pathology, while the lower gene group represent those downregulated with low-grade pathology (reviewed in ref. 39).
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and upregulation of various p53 target genes including TP53I5 
(6.7-fold), TP53I11 (4.3-fold), TP53I3 (1.3-fold) and TP53INP2 
(1.3-fold) (Fig. 1A). These findings would concur with previous 
demonstrations that HDACIs can downregulate abnormal p53 
gene products, while also restoring “p53-like” pathways to can-
cer cells lacking functions (including apoptosis) of that tumor 
suppressor.65-67 Notably, we also observed AR42 upregulation of 
a p53 target microRNA gene, miR-34, whose re-expression, in 
ovarian and other cancers, strongly associates with activation of 
numerous p53 response pathways.17,68
Epigenetic modifications also regulate differentiation states in 
normal stem cells and adult tissues,1,16 and it has been shown that 
even highly aggressive cancer cells possess considerable phenotypic 
“plasticity,” associated with chromatin-remodeling ability.41,69 As 
HDACIs and DNA methyltransferase inhibitors (DNMTIs) are 
well-characterized differentiating agents, it is possible that these 
chromatin-relaxing agents could “reset” cancer progenitor cells 
suggest that epigenetic aberrations may play an analogous or even 
greater role in enhanced Wnt signaling. Indeed numerous studies 
have now demonstrated chromatin-related silencing of the Wnt 
antagonists TAK1, SFRP1, ICAT, WIF1 and DKK1,41,42 genes 
we also identified as upregulated by AR42 (Figs. 2C and 5A 
and Table 3).
EMT and Wnt also represent two interdependent pathways 
hypothesized to facilitate the genesis, proliferation and tumor 
propagation characteristics of “cancer stem cells” (CSCs), neo-
plastic progenitors believed to govern (or possibly exacerbate) 
most or all malignant phenotypes.41,62 Additionally, the ovarian 
cancer cells used in this study, CP70, are highly aggressive, inva-
sive and chemoresistant,36,37,56 three traits associated with cancer 
“stemness.”14,55,62 CP70 cells also possess dysfunctional p53,37 
whose loss promotes self-renewal of normal and leukemia stem 
cells.63,64 Interestingly, our gene expression microarray results 
indicated a slight downregulation of p53 (0.7-fold, Fig. 4A), 
Figure 5. experimental validation of ar42-decreased canonical Wnt signaling. (a) Quantitative pCr expression validation of selected microarray 
ar42-altered genes alter, including members of the Wnt signal pathway (TAK1, SFRP1), the epithelial-to-mesenchymal transition (ATF1), and cell cycle 
negative regulation (14-3-3σ). (*p < 0.05 vs. control). (B) Quantification of Wnt pathway signaling following 24 h, 1.0 μM ar42 treatment of Cp70 cells 
transfected with a Wnt signal TOpFlash luciferase reporter.40 relative luminescence units (rLUs) were determined by normalizing the luminescence 
of TOpFlash-possessing cells to the total cellular protein from each lysate and to luminescence from mutant control vector (“FOpFlash”)-transfected 
cells.70 (C) Western blot analysis of cytoplasmic vs. nuclear extracts from Cp70 ovarian cancer cells treated for 24 h with DMsO vehicle (“control,” lanes 
2 and 6), 1.0 μM ar42 (lanes 3 and 7), or 1.0 μM vorinostat (lanes 1 and 5). (D) Quantification of western blot using ImageJ software (*p < 0.05, vs. 
control).
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inhibitor (HDACI) studies, CP70 cells (~70% confluency) were 
treated with vehicle (DMSO) control, 1.0 μM vorinostat or 1.0 
μM AR42 for 24–72 h, harvested from culture plates, centrifuged 
and the pellets then further processed or stored at -80°C.
Mature miR and protein-coding (mRNA) gene expres-
sion. Total RNA was isolated from 24- or 48-h HDACI-treated 
or -untreated CP70 cells by suspension in TRIzol reagent 
(Invitrogen), as we have previously described in reference 70. 
Global analyses of mature miR expression were kindly per-
formed by Dr Michael Thomson (Vanderbilt University), using 
a 124-feature custom microarray.71 For gene expression analy-
ses, total RNA was qualified (Agilent Bioanalyzer 2100, Agilent 
Technologies), reverse transcribed to cDNA, labeled with Cy3-
conjugated nonamers (Roche NimbleGen) and purified and 
hybridized to Human Gene Expression 385K Arrays, according 
to the manufacturer’s (Roche Nimblegen) protocol. Following 
washing, the hybridized arrays were then scanned (single color 
green) using an Axon GenePix Professional 4200A Scanner 
(Molecular Devices).
Data processing and functional analyses of miR and mRNA 
expression. Scanned microarray images (GenePix files) were 
aligned using center fiducial controls, and the gridded files 
imported into NimbleScan analysis software (v2.5), followed 
by quantile normalization,72 and gene calls made using Robust 
Multichip Averaging.72 MicroRNA (miRNA) expression data 
(.xlsx format), provided by Dr Thomson, was similarly processed 
to a differentiation-competent, drug-sensitive phenotype,14,16,54,62 
thus decreasing the tumor subpopulation most responsible for 
perpetuating malignant phenotypes.14,41,55,62
Taken together, these combined computational and experi-
mental approaches suggest that AR42 can upregulate tumor sup-
pressor genes (including miRNAs) and antagonize specific tumor 
progression signal pathways, including two embryonic develop-
ment cascades implicated in the genesis and maintenance of can-
cer stem cells. Overall, these findings suggest that AR42 (and 
perhaps other epigenetic modifiers), in possible combination with 
pathway-specific antagonists, might be clinically beneficial for 
the therapy of chemoresistant, high-grade serous ovarian cancer.
Materials and Methods
Reagents, cell culture and HDAC inhibitor (HDACI) treat-
ments. Cell culture reagents were obtained from Invitrogen 
Gibco/BRL. Except where specified, antibodies were purchased 
from KPL Laboratories. All other reagents were purchased from 
Sigma-Aldrich. For the specific study of advanced, chemoresistant 
ovarian cancer, we used the p53-dysfunctional CP70 ovarian can-
cer cell line previously shown resistant to platinum, adriamycin 
and ionizing radiation36,37 (a kind gift from Dr Thomas Hamilton, 
Fox Chase Cancer Center). The HDACIs AR425 and vorinostat3 
were kind gifts from Drs Ching-Shih Chen and Samuel Kulp 
(College of Pharmacy, Ohio State University). For all HDAC 
Figure 6. experimental evaluation of the roles of caspase activity, reactive oxygen species (rOs) and mitochondrial disruption43,44 in hDaCI-mediated 
cell death. (a) Dose-dependent growth inhibition of Cp70 cells treated for 48 h with increasing doses of ar42 in the continuous presence or absence of 
20 μM pan-caspase inhibitor z-VaD-fmk. (B) hDaCI dependence upon rOs, as determined by comparing 50% growth inhibitory doses (GI50 doses) of 
Cp70 cells treated for 24 h with 1.0 μM vorinostat or 1.0 μM ar42 in the absence or presence of 15 mM antioxidant N-acetylcysteine (“NaC”). (C) Fluo-
rescent micrographs of Cp70 cells treated for 24 h with 1.0 μM ar42 (upper part) or 1.0 μM vorinostat (lower part) and exposed to the cell-permeable, 
mitochondrial inner membrane-accumulating fluorophore JC-1.46 at normal membrane potentials, mitochondria-aggregated JC-1 fluoresces red, 
while loss of membrane potential results in JC-1 aggregation failure and monomer fluorescence emission of green.46 (*p < 0.05, vs. control).
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Assessment of Wnt activity (β-catenin nuclear transloca-
tion). For western blot assays, CP70 cells were treated with 
vehicle (DMSO), 1.0 μM AR42 or 1.0 μM vorinostat for 
48 h, followed by isolation of total cytoplasmic or total nuclear 
protein, using a nuclear extraction kit (Active Motif ). Fifteen 
micrograms of nuclear or cytoplasmic protein (with β-catenin 
positive control cell lysate, Lab Vision) were then electropho-
resed through 8% SDS-PAGE, transferred to nylon membranes, 
blocked with 5% milk and incubated overnight with diluted 
primary antibodies against activated (unphosphorylated) 
β-catenin (Lab Vision) and GAPDH (a gel-loading control, 
Millipore). Membranes were then washed and incubated with 
peroxidase-conjugated anti-rabbit or anti-mouse IgG second-
ary antibodies for 60 min, washed again, placed for 1 min in 
SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Fisher Scientific), and exposed to film (Kodak) for 2 min. 
Western blot band intensities were then determined by scanning 
and quantification using ImageJ Java-based imaging software 
(Research Services Branch, National Institute of Mental Health, 
rsb.info.nih.gov/ij).
Assessment of Wnt signal transactivity by luciferase reporter 
assay. For determination of Wnt signal activity at the pathway 
level, CP70 cells were grown in 6-well plates to 60–70% con-
fluency. Using Lipofectamine 2000 (Invitrogen), cells were 
then transfected for 24 h with 1.0 μg of the luciferase reporter 
TOPFlash (a construct possessing four Wnt signal-transactivat-
ing TCF/LEF-binding sites ligated to the gene luc) or 1.0 μg 
of its negative control FOPflash (having four mutant luc-ligated 
TCF/LEF-binding sites).40 Both TOPflash and FOPflash were 
purchased from Millpore. TOPFlash- or FOPFlash-transfected 
cells were then treated with DMSO vehicle or 1.0 μM AR42 or 
for 48 h, washed 2x with cold PBS, placed in 1x Reporter Lysis 
Buffer (Promega) and stored at -80°C for at least 1 h. Following 
one freeze-thaw cycle, Luciferase Assay Reagent (Promega) 
was added to the AR42-treated or -untreated cell lysates, with 
luminescence intensity detected by a TD-20/20 luminometer 
(Turner Designs). Raw TOPFlash and FOPFlash luminescence 
values were then normalized for protein concentration, and the 
normalized TOPFlash:FOPFlash ratios then used to quantify 
Wnt reporter activity in untreated vs. AR42-treated CP70 cell 
lysates.70
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using quantile normalization.72 Unsupervised hierarchical clus-
tering (a control for reproducibility and distinctiveness of the 
treatment groups) was then performed, using the integrated soft-
ware platform Expander (EXPression ANalyzer and DisplayER, 
acgt.cs.tau.ac.il/expander, Tel Aviv University, Israel).29
In this study, rather than restricting potential HDACI anti-
neoplastic mechanisms to limited numbers of genes, we used a 
“systems biology” approach28,29 to delineate specific signal path-
way alterations and reveal possible transcriptional regulatory net-
works mediating the anti-ovarian cancer effects AR42. To that 
end, we compared genome-wide protein-coding gene (mRNA) 
and mature miRNA expression in AR42-treated vs. -untreated 
CP70 cells. Computationally, we first identified transcription 
factor (TF)-encoding genes transcribed in positive correlation 
with downstream “target” genes. Our rationale for the latter was 
that altered TF activity could result in pleitropic (and amplified) 
drug effects on specific pathways/processes.28,29 By this approach, 
using  a signal intensity fold change of 1.5, we identified TF genes 
whose expression positively correlated with AR42-altered genes 
having their cognate binding site motifs31 using the visualization 
tool ECR (evolutionary conserved region) Browser (ecrbrowser.
dcode.org).30 Those TF/target gene sets were then subjected 
to functional analysis, using the Web tool BiNGO v2.31.32 
Following normalization and microarray processing, we iden-
tified all genes 1.5-fold up or downregulated by 48 h, 1.0 μM 
AR42 treatment. We then located the transcription start sites 
(TSSs) of those altered genes, as reported in research literature 
and publically available human genome databases.30 Following 
identification of TSSs, we explored the presence of evolution-
arily conserved transcription factor-binding sites (TFBSs) within 
4 kb regions encompassing the TSSs, using the ECR browser 
(ecrbrowser.dcode.org).30,31 Genes encoding TFs having cognate 
TFBSs within misexpressed (protein-coding) genes were then 
identified (also by a fold-change cutoff of 1.5) and subjected to 
BiNGO functional analysis32 to determine gene ontology (GO) 
biological process terms (Table 1).
Assessments of mitochondrial (intrinsic) or death recep-
tor (extrinsic) apoptosis. To examine AR42 caspase depen-
dence, CP70 cells were treated for 48-h with 1.0 μM AR42, 
in the absence or presence of 20 μM pan-caspase inhibitor 
z-VAD-fmk (Promega). To assess the role of reactive oxygen 
species43 in AR42-induced apoptosis CP70 cells were similarly 
treated in the presence or absence of 15 mM of the antioxidant 
N-acetylcysteine. Separately, CP70 cells were grown on micro-
scope coverslips, treated for 48 h with 1.0 μM vorinostat or 1.0 
μM AR42, incubated for 20 min with 500 ng of the cationic 
mitochondrion-accumulating dye, JC-1 (Cayman Chemical 
Company), and photographed using a fluorescence microscope 
(Carl Zeiss) with filters for excitation/emission wavelengths of 
485/530 nm (green) or 535/590 nm (red). Under normal mito-
chondrial transmembrane potential (ΔΨm), JC-1 self-aggregates 
within the mitochondrial inner membrane space, fluorescing 
red (multimeric JC-1). Loss of ΔΨm, however (as occurs during 
mitochondrial disruption), results in JC-1 mitochondrial aggre-
gation failure, with JC-1 monomers remaining in the cytosol, 
fluorescing green.46
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